AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

- 1-80. (Canceled)
- 81. (Previously Presented) A compound of the formula

wherein R₄ and R₅ together form cyclohexyl.

82. (Previously Presented) A compound of the formula

wherein R₁ is aralkyl, arylheterocyclylalkyl, alkylaminocarbonyl, alkenylaminocarbonyl, arylaminocarbonyl, alkoxyalkyl, aryloxyalkyl, or aralkoxyalkyl, wherein the aryl portion is phenyl or naphthyl and the alkyl portion is a C₁-C₆ alkyl, and the heterocyclyl is a 3-7 membered ring having at least one of N, O, and S; R₂ is dicarboxyalkyl, R₃ is carboxyalkyl, R₄ and R₅ together form cycloalkyl, and R₆ is a C₂-C₄ alkenylenyl group.

83. (Previously Presented) The compound of claim 82, which has the formula:

- 84. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 81.
- 85. (Currently Amended) A method for inhibiting an SH2 domain from binding with a phosphoprotein comprising contacting an SH2 domain with <u>an effective amount of</u> a compound of claim 81.
- 86. (Currently Amended) A method for preventing or treating a disease, state, or e-ondition breast cancer in a mammal comprising administering to the mammal an effective amount of a compound of claim 81.
- 87. (Currently Amended) A method for inhibiting cell motility or angiogenesis in a mammal comprising administering to said mammal an effective amount of a compound claim 81.

88-89. (Canceled)

90. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and <u>an effective amount of</u> a compound of claim 82.

- 91. (Currently Amended) A method for inhibiting an SH2 domain from binding with a phosphoprotein comprising contacting an SH2 domain with <u>an effective amount of</u> a compound of claim 82.
- 92. (Currently Amended) A method for preventing or treating a disease, state, or condition breast cancer in a mammal comprising administering to the mammal an effective amount of a compound of claim 82.
- 93. (Currently Amended) A method for inhibiting cell motility or angiogenesis in a mammal comprising administering to said mammal an effective amount of a compound of claim 82.
- 94. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 83.
- 95. (Currently Amended) A method for inhibiting an SH2 domain from binding with a phosphoprotein comprising contacting an SH2 domain with <u>an effective amount of</u> a compound of claim 83.
- 96. (Currently Amended) A method for preventing or treating a disease, state, or eondition breast cancer in a mammal comprising administering to the mammal an effective amount of a compound of claim 83.
- 97. (Currently Amended) A method for inhibiting cell motility or angiogenesis in a mammal comprising administering to said mammal an effective amount of a compound of claim 83.